Application of a Novel Prediction Model for Predicting 2-Year Risk of Non-Alcoholic Fatty Liver Disease in the Non-Obese Population with Normal Blood Lipid Levels: A Large Prospective Cohort Study from China

References

• Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999–2014.e1. doi:10.1053/j.gastro.2019.11.312
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2021;73(3):1194–1198. doi:10.1002/hep.31420
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta‐analysis. Hepatology. 2019;70(4):1119–1133. doi:10.1002/hep.30702
   PubMed Web of Science ®Google Scholar
• Estes C, Anstee QM, Arias-Loste MT, et al. Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030. J Hepatol. 2018;69(4):896–904. doi:10.1016/j.jhep.2018.05.036
   PubMed Web of Science ®Google Scholar
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1):S47–S64. doi:10.1016/j.jhep.2014.12.012
   PubMed Web of Science ®Google Scholar
• Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330. doi:10.1038/nrgastro.2013.41
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Non-alcoholic fatty liver disease–a global public health perspective. J Hepatol. 2019;70(3):531–544. doi:10.1016/j.jhep.2018.10.033
   PubMed Web of Science ®Google Scholar
• Fan J-G, Kim S-U, Wong VW-S. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862–873. doi:10.1016/j.jhep.2017.06.003
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65(8):1109–1123.
   PubMed Web of Science ®Google Scholar
• Liu CJ. Prevalence and risk factors for non‐alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol. 2012;27(10):1555–1560. doi:10.1111/j.1440-1746.2012.07222.x
   PubMed Web of Science ®Google Scholar
• Moore MP, Cunningham RP, Dashek RJ, Mucinski JM, Rector RS. A fad too far? Dietary strategies for the prevention and treatment of NAFLD. Obesity. 2020;28(10):1843–1852. doi:10.1002/oby.22964
   PubMed Web of Science ®Google Scholar
• Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–846. doi:10.1016/j.jhep.2017.05.016
   PubMed Web of Science ®Google Scholar
• Tu Q, Hu C, Zhang H, et al. Establishment and validation of novel clinical prognosis nomograms for luminal a breast cancer patients with bone metastasis. Biomed Res Int. 2020;2020. doi:10.1155/2020/1972064
   Web of Science ®Google Scholar
• Sun D-Q, Wu S-J, Liu W-Y, et al. Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study. BMJ Open. 2016;6(12):e013781. doi:10.1136/bmjopen-2016-013781
   PubMed Web of Science ®Google Scholar
• De Zeng M, Fan JG, Lu LG, et al. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis. 2008;9(2):108–112. doi:10.1111/j.1751-2980.2008.00331.x
   PubMed Web of Science ®Google Scholar
• Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) the TRIPOD statement. Circulation. 2015;131(2):211–219. doi:10.1161/CIRCULATIONAHA.114.014508
   PubMed Web of Science ®Google Scholar
• Cai X, Ji L, Liu S, et al. Derivation and validation of a prediction model for predicting the 5-year incidence of type 2 diabetes in non-obese adults: a Population-Based Cohort Study. Diabetes Metab Syndr Obes. 2021;14:2087–2101. doi:10.2147/DMSO.S304994
   PubMed Web of Science ®Google Scholar
• Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–133. doi:10.1002/hep.29466
   PubMed Web of Science ®Google Scholar
• Kim D, Kim WR. Nonobese fatty liver disease. Clin Gastroenterol Hepatol. 2017;15(4):474–485. doi:10.1016/j.cgh.2016.08.028
   PubMed Web of Science ®Google Scholar
• Cai X, Aierken X, Ahmat A, et al. A nomogram model based on noninvasive bioindicators to predict 3-year risk of nonalcoholic fatty liver in nonobese mainland chinese: a Prospective Cohort Study. Biomed Res Int. 2020;2020:1–12. doi:10.1155/2020/8852198
   Web of Science ®Google Scholar
• Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71(2):371–378. doi:10.1016/j.jhep.2019.03.033
   PubMed Web of Science ®Google Scholar
• Hu C, Yang J, Huang Z, et al. Diagnostic and prognostic nomograms for bone metastasis in hepatocellular carcinoma. BMC Cancer. 2020;20(1):1–11. doi:10.1186/s12885-020-06995-y
   Web of Science ®Google Scholar
• Cen C, Wang W, Yu S, et al. Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease. Hepatol Int. 2020;14(5):808–816. doi:10.1007/s12072-020-10065-7
   PubMed Web of Science ®Google Scholar
• Xue M, Yang X, Zou Y, et al. A non-invasive prediction model for non-alcoholic fatty liver disease in adults with type 2 diabetes based on the population of Northern Urumqi, China. Diabetes Metab Syndr Obes. 2021;14:443. doi:10.2147/DMSO.S271882
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82–97. doi:10.1016/j.metabol.2018.11.014
   PubMed Web of Science ®Google Scholar
• Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014;20(28):9330.
   PubMed Web of Science ®Google Scholar
• Fukuda Y, Hashimoto Y, Hamaguchi M, et al. Triglycerides to high‐density lipoprotein cholesterol ratio is an independent predictor of incident fatty liver; a population‐based cohort study. Liver Int. 2016;36(5):713–720. doi:10.1111/liv.12977
   PubMed Web of Science ®Google Scholar
• Pacifico L, Bonci E, Andreoli G, et al. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents. Nutr Metab Cardiovasc Dis. 2014;24(7):737–743. doi:10.1016/j.numecd.2014.01.010
   PubMed Web of Science ®Google Scholar
• Chen Z, Qin H, Qiu S, Chen G, Chen Y. Correlation of triglyceride to high-density lipoprotein cholesterol ratio with nonalcoholic fatty liver disease among the non-obese Chinese population with normal blood lipid levels: a retrospective cohort research. Lipids Health Dis. 2019;18(1):1–7. doi:10.1186/s12944-019-1104-6
   PubMed Web of Science ®Google Scholar
• Li Y, Zheng R, Li J, Feng S, Wang L, Huang Z. Association between triglyceride glucose-body mass index and non-alcoholic fatty liver disease in the non-obese Chinese population with normal blood lipid levels: a secondary analysis based on a prospective cohort study. Lipids Health Dis. 2020;19(1):1–11. doi:10.1186/s12944-019-1182-5
   PubMed Web of Science ®Google Scholar
• Lucero D, Miksztowicz V, Macri V, et al. Overproduction of altered VLDL in an insulin-resistance rat model: influence of SREBP-1c and PPAR-α. Clin Investig Arterioscler. 2015;27(4):167–174. doi:10.1016/j.arteri.2014.11.002
   PubMedGoogle Scholar
• Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2012;32(9):2104–2112. doi:10.1161/ATVBAHA.111.241463
   PubMed Web of Science ®Google Scholar
• Alves‐Bezerra M, Cohen DE. Triglyceride metabolism in the liver. Compr Physiol. 2011;8(1):1–22.
   Google Scholar
• Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013;48(4):434–441. doi:10.1007/s00535-013-0758-5
   PubMed Web of Science ®Google Scholar
• Smith GI, Polidori DC, Yoshino M, et al. Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics. J Clin Invest. 2020;130(6):3305–3314. doi:10.1172/JCI136756
   PubMed Web of Science ®Google Scholar
• Hossain IA, Shah MMR, Rahman MK, Ali L. Gamma glutamyl transferase is an independent determinant for the association of insulin resistance with nonalcoholic fatty liver disease in Bangladeshi adults: association of GGT and HOMA-IR with NAFLD. Diabetes Metab Syndr. 2016;10(1):S25–S29. doi:10.1016/j.dsx.2015.09.005
   PubMedGoogle Scholar
• Zou Y, Zhong L, Hu C, Sheng G. Association between the alanine aminotransferase/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study. Lipids Health Dis. 2020;19(1):1–10. doi:10.1186/s12944-020-01419-z
   PubMed Web of Science ®Google Scholar
• Fan N, Peng L, Xia Z, et al. Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis. 2019;18(1):1–6. doi:10.1186/s12944-019-0986-7
   PubMed Web of Science ®Google Scholar
• Kim JW, Lee KJ, Yang HR, et al. Prevalence and risk factors of elevated alanine aminotransferase among Korean adolescents: 2001–2014. BMC Public Health. 2018;18(1):1–8. doi:10.1186/s12889-018-5548-9
   Web of Science ®Google Scholar
• Shen X, Fang Cai J, Sheng Gao J, et al. Nonalcoholic fatty liver disease and risk of diabetes: a prospective study in China. Endocr Pract. 2018;24(9):823–832. doi:10.4158/EP-2018-0098
   PubMed Web of Science ®Google Scholar
• Zheng R, Du Z, Wang M, Mao Y, Mao W. A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease. Lipids Health Dis. 2018;17(1):1–9. doi:10.1186/s12944-018-0913-3
   PubMed Web of Science ®Google Scholar
• Sinn DH, Gwak G-Y, Park HN, et al. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am J Gastroenterol. 2012;107(4):561–567. doi:10.1038/ajg.2011.400
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu W, Zhai T, You J, Chen Y. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway. Acta Phar Sin B. 2019;9(4):745–757. doi:10.1016/j.apsb.2019.02.006
   PubMed Web of Science ®Google Scholar
• Wang R, Lu Q, Feng J, et al. Coexistence of non-alcoholic fatty liver disease with elevated alanine aminotransferase is associated with insulin resistance in young Han males. Endocrine. 2012;41(1):70–75. doi:10.1007/s12020-011-9511-0
   PubMed Web of Science ®Google Scholar
• Franzini M, Fornaciari I, Fierabracci V, et al. Accuracy of b‐GGT fraction for the diagnosis of non‐alcoholic fatty liver disease. Liver Int. 2012;32(4):629–634. doi:10.1111/j.1478-3231.2011.02673.x
   PubMed Web of Science ®Google Scholar
• Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Off J Am Coll Gastroenterol. 2017;112(1):18–35. doi:10.1038/ajg.2016.517
   PubMed Web of Science ®Google Scholar
• Saoi M, Sasaki K, Sagawa H, et al. High throughput screening of serum γ-glutamyl dipeptides for risk assessment of nonalcoholic steatohepatitis with impaired glutathione salvage pathway. J Proteome Res. 2019;19(7):2689–2699. doi:10.1021/acs.jproteome.9b00405
   PubMed Web of Science ®Google Scholar
• Kang YH, Min HK, Son SM, Kim IJ, Kim YK. The association of serum gamma glutamyltransferase with components of the metabolic syndrome in the Korean adults. Diabetes Res Clin Pract. 2007;77(2):306–313. doi:10.1016/j.diabres.2006.11.009
   PubMed Web of Science ®Google Scholar
• Bullón-Vela V, Abete I, Tur JA, et al. Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. Ther Adv Endocrinol Metab. 2020;11:2042018820958298. doi:10.1177/2042018820958298
   Web of Science ®Google Scholar
• Ndrepepa G, Kastrati A. Gamma-glutamyl transferase and cardiovascular disease. Ann Transl Med. 2016;4(24):481. doi:10.21037/atm.2016.12.27
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Chan W-K, Goh G-B-B, et al. Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: the gut and obesity Asia initiative. World J Gastroenterol. 2020;26(19):2416. doi:10.3748/wjg.v26.i19.2416
   PubMed Web of Science ®Google Scholar
• Lallukka S, Yki-Järvinen H. Non-alcoholic fatty liver disease and risk of type 2 diabetes. Best Pract Res Clin Endocrinol Metab. 2016;30(3):385–395. doi:10.1016/j.beem.2016.06.006
   PubMed Web of Science ®Google Scholar
• Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Alanine aminotransferase, γ-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care. 2009;32(4):741–750. doi:10.2337/dc08-1870
   PubMed Web of Science ®Google Scholar
• Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264–1281. e4. doi:10.1053/j.gastro.2018.12.036
   PubMed Web of Science ®Google Scholar